Pinion Immunotherapeutics

Pinion Immunotherapeutics is a biotechnology company dedicated to discovering and developing transformative therapies for neurodegenerative disorders by targeting the brain's innate immune system. The company focuses on modulating microglia, the primary immune cells of the central nervous system, to address the underlying drivers of neuroinflammation and protein aggregation. Led by renowned neuroimmunology expert Dr. Richard Ransohoff, Pinion utilizes proprietary insights into myeloid cell biology to identify novel therapeutic targets. Their current research efforts are centered on high-impact indications, including Alzheimer's disease and other forms of dementia. By restoring healthy microglial function, the company aims to slow or halt the progression of debilitating neurological conditions.